Virotherapy
Virotherapy
About the clinic
The clinic in southern Germany is a private specialist clinic with a focus on oncology. It offers:
Questions about virotherapy?
Contact us for a non-binding consultation.
Virotherapy - Cancer therapy with oncolytic viruses - RIGVIR®
Healing virus “Rigvir” can double the survival rate in cancer.
This new treatment, which breaks down cancer cells, stimulates the immune system and promotes the self-destruction of cancer cells.
The potential of viruses was already recognized at the beginning of the last century. The approach of oncolytic virotherapy was first mentioned in the literature in 1904, but was forgotten for almost 100 years and has only been intensively pursued again in recent years.
Mode of action
The viruses infect the tumor cells, multiply in them and destroy them as part of the lytic cycle of viral replication, in which the infected cell is opened at the end to release the viruses replicated in it. The cancer cell dies in the process, the released viruses infect further cancer cells and so on.
In addition, cell lysis releases tumor-specific antigens that induce an immune response.
Virus ECHO-7
Intensive research is being carried out worldwide into how viruses can be used effectively in cancer therapy. Virus therapy is seen as a great source of hope in the fight against cancer. To date, there is only one virus in the world that has not been genetically modified and that will be groundbreaking for modern cancer therapy.
Virus ECHO-7-RIGVIR®
Virotherapy is a gentle and safe treatment method. RIGVIR was synthesized from the ECHO-7 virus, which occurs naturally in the intestines of young children. The virus selectively targets malignant cells, which it invades before multiplying in a process known as oncolysis and ultimately destroying the cancer cell. In addition, the virus makes the cancer visible to the patient's immune system and thus enables it to be fought. RIGVIR is the only drug that contains live, natural viruses with oncolytic* properties. This makes it capable of recognizing and destroying malignant cancer cells.
*Oncolytic viruses are viruses that multiply specifically in cancer cells and thereby destroy them (oncolysis).
Main areas of application of oncolytic virotherapy with RIGVIR®
The treatment is effective against a variety of cancers such as:
Melanomas
Pancreatic cancer
Colorectal cancer
Bladder cancer
Kidney cancer
Prostate cancer
Lung cancer
Uterine cancer
Lymphosarcomas
Treatment with Vieren is carried out in our clinic in Germany on an outpatient basis and according to an individually developed treatment plan.
Virus therapy consists of several injections according to a predetermined treatment plan. After injection into the body, the virus finds malignant tumor cells and destroys them by specifically multiplying the RIGVIR® virus in cancer cells (oncolysis). Healthy cells are not damaged.
RIGVIR is administered over a period of three years with a series of injections.
RIGVIR® is injected intramuscularly, preferably near the lymph node closest to the cancer.
In order to minimize the risk of metastases spreading, it is recommended to start oncolytic virotherapy before surgery or to undergo dendritic cell therapy (DCT). If there are no metastases, one ampoule is usually administered every 4 weeks for the first quarter of the year. In the case of metastases, a weekly injection is planned for the first quarter of the year.
The longer RIGVIR® virotherapy is continued, the longer the intervals become.
Studies from the Latvian Virotherapy Center in Riga / Latvia on RIGVIR® Virotherapy show
Studies from the Latvian Virotherapy Center in Riga / Latvia on RIGVIR® virotherapy show that treatment should be continued for 3 years in order to keep the risk of relapse as low as possible.
The intervals between injections are then up to 3 months. The virotherapy treatment is controlled and monitored via the blood count and the corresponding blood parameters.
Virotherapy with the drug RIGVIR® is characterized by high therapeutic efficacy, insignificant side effects and the ability to activate the immune system.
The most common side effect is a slightly increased body temperature, which lasts for 1-3 days, or a slight chill.
Publications on virotherapy
Eur J Pharmacol
2018 Oct 15:837:117-126.
doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1.
The advent of oncolytic virotherapy in oncology: The Rigvir® story
Pēteris Alberts 1, Andra Tilgase 2, Agnija Rasa 2, Katrīna Bandere 2, Dite Venskus 2
Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180.PMID: 26193376 Free PMC article.
Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D.APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26.PMID: 27457663
Hietanen E, Koivu MKA, Susi P.Viruses. 2022 Mar 4;14(3):525. doi: 10.3390/v14030525.PMID: 35336934 Free PMC article.
Rasa A, Alberts P.J Appl Toxicol. 2023 May;43(5):620-648. doi: 10.1002/jat.4408. Epub 2022 Nov 7.PMID: 36299168 Review.
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA, Beaulieu C, Patel RB, Lowe DK.Ann Pharmacother. 2017 Aug;51(8):675-681. doi: 10.1177/1060028017702654. Epub 2017 Mar 28.PMID: 28351167 Review.
Authorization
Free advice on virotherapy
Our specialized team will be happy to answer your questions about virotherapy and create an individual treatment plan for you.